Inflarx N.V. ( (IFRX) ) has released its Q4 earnings. Here is a breakdown of the information Inflarx N.V. presented to its investors.
InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system, with a primary emphasis on its lead product candidate, vilobelimab, and the oral C5aR inhibitor, INF904.
In its latest earnings report, InflaRx highlighted several significant achievements, including the European Commission’s approval of GOHIBIC® (vilobelimab) for treating SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) and progress in clinical trials for other inflammatory conditions.
Key financial metrics revealed a net loss of €46.1 million for 2024, with revenues from product sales amounting to €0.2 million. The company successfully raised €28.7 million through a public offering, extending its cash runway into 2027. Strategic advancements include reaching a patient recruitment milestone in a Phase 3 trial for pyoderma gangrenosum and initiating a Phase 2a trial for INF904.
Looking ahead, InflaRx is poised for a catalyst-rich year in 2025, with anticipated interim analysis for its Phase 3 trial in pyoderma gangrenosum and topline data from the INF904 Phase 2a trial. The company remains focused on advancing its pipeline and exploring commercial partnerships in the European Union.